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Abstract
Background: Envenomations by the snake Bothrops asper represent a serious medical problem in Central America and parts
of South America. These envenomations concur with drastic local tissue pathology, including a prominent edema. Since
lymph flow plays a role in the maintenance of tissue fluid balance, the effect of B. asper venom on collecting lymphatic
vessels was studied.
Methodology/Principal Findings: B. asper venom was applied to mouse mesentery, and the effects were studied using an
intravital microscopy methodology coupled with an image analysis program. B. asper venom induced a dose-dependent
contraction of collecting lymphatic vessels, resulting in a reduction of their lumen and in a halting of lymph flow. The effect
was reproduced by a myotoxic phospholipase A2 (PLA2) homologue isolated from this venom, but not by a hemorrhagic
metalloproteinase or a coagulant thrombin-like serine proteinase. In agreement with this, treatment of the venom with
fucoidan, a myotoxin inhibitor, abrogated the effect, whereas no inhibition was observed after incubation with the
peptidomimetic metalloproteinase inhibitor Batimastat. Moreover, fucoidan significantly reduced venom-induced footpad
edema. The myotoxic PLA2 homologue, known to induce skeletal muscle necrosis, was able to induce cytotoxicity in
smooth muscle cells in culture and to promote an increment in the permeability to propidium iodide in these cells.
Conclusions/Significance: Our observations indicate that B. asper venom affects collecting lymphatic vessels through the
action of myotoxic PLA2s on the smooth muscle of these vessels, inducing cell contraction and irreversible cell damage. This
activity may play an important role in the pathogenesis of the pronounced local edema characteristic of viperid snakebite
envenomation, as well as in the systemic biodistribution of the venom, thus representing a potential therapeutical target in
these envenomations.
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Introduction
Envenomations due to snakebites constitute a relevant, albeit
neglected, health problem in many regions of the world, especially
in rural areas of Africa, Asia, Latin America and Papua-New
Guinea, where they have a high toll in terms of mortality and
morbidity [1–4]. Envenomations by species classified in the family
Viperidae, i.e. true vipers and pit vipers, and by some species of
the family Elapidae, mostly cobras, are characterized by
prominent local pathological effects which develop at the
anatomical region where venom is injected [5,6]. The rapid
development of these local effects, together with the partial
inability of antivenoms to neutralize them, often result in the
appearance of permanent physical and psychological sequelae in
these patients [2,4,7].
In Latin America, the vast majority of snakebite envenomations
are inflicted by species of the genus Bothrops [6,8,9]. Bothrops asper,
a species widely distributed in southern Mexico, Central America
and the northern areas of South America [10], is responsible for
the majority of cases in these regions [6,11,12]. Owing to the size
of this species, and to the large volume of venom that it delivers,
these envenomations involve a prominent local pathology which
includes edema, hemorrhage, blistering, dermonecrosis and
myonecrosis [6,7,9]. The pathogenesis of these pathological
alterations has been investigated in experimental models. These
effects result mostly from the combined action of Zn2+-dependent
metalloproteinases (SVMPs) and myotoxic phospholipases A2
(PLA2) [7,13–15]. SVMPs are able to degrade extracellular matrix
components, such as those present in the basement membrane of
microvessels and at the dermal-epidermal junction [16,17],
whereas myotoxic PLA2s disrupt the integrity of the plasma
membrane of skeletal muscle fibers [15]. In addition, a prominent
inflammatory reaction of multifactorial origin develops, resulting
in a pronounced edema and an inflammatory cell infiltrate [6,7].
Such edema, in turn, contributes to hypovolemia and may
promote increments in intracompartmental pressures in some
muscle compartments, thus inducing further ischemia and tissue
damage [12,18].
In spite of the advances in our understanding of venom-induced
damage to muscle tissue and blood vessels, there is a gap in our
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understanding of the alterations occurring in lymphatic vessels as a
consequence of these envenomations. The lymphatic vasculature
plays a key role in the maintenance of fluid balance in the tissues,
by removing fluid from the interstitial compartment [19–21]. The
failure of lymphatics to fulfill this role, either by hereditary or
acquired alterations, results in lymphedema [19,20,22–24]. In
addition, lymphatics play critical functions in the immune
surveillance and in the absorption of fat [20,21]. In the case of
snakebite envenomations, lymphatics contribute to the systemic
absorption of venom toxins from the tissues [25]. Therefore, the
study of potential effects of snake venoms on the structure and
function of lymphatic vessels is relevant to understand the local
pathology of these envenomations, and may have implications in
terms of the pathogenesis of edema and the absorption of venom
components from the tissues. The present study was designed to
assess the effect of the venom of B. asper on the structure and
function of mouse mesenteric collecting lymphatic vessels, and to
identify which components in the venom are responsible for these
alterations. Our results provide new insights into the understand-
ing of toxin-mediated lymphatic flow impairment and delineate a
possible involvement of these vessels in the pathophysiology of
snakebite envenomation.
Methods
Venom and toxins
Venom was obtained from adult specimens of B. asper collected
in the Pacific region of Costa Rica and kept at Instituto Clodomiro
Picado. In some experiments, venom from neonate B. asper
specimens (less than 30 days old) was also used. After collection,
venom was lyophilized and stored at 220uC. Venom solutions
were prepared immediately before the experiments, using 0.12 M
NaCl, 0.04 M phosphate, pH 7.2 (PBS) as solvent. Myotoxin II, a
phospholipase A2 homologue, was purified from the venom by
cation-exchange chromatography on CM-Sephadex C-25, as
previously described [26,27]. Hemorrhagic metalloproteinase
BaP1 was isolated by cation-exchange chromatography on CM-
Sephadex C-25 and affinity chromatography on Affi-gel Blue, as
described [28,29]. A thrombin-like serine proteinase was isolated
by benzamidine Sepharose affinity chromatography and anion-
exchange chromatography on DEAE-Sepharose [30]. Homoge-
neity of the isolated toxins was assessed by sodium dodecyl sulfate
(SDS)-polyacrylamide gel electrophoresis under reducing condi-
tions [31].
Intravital microscopy
Groups of five CD-1 mice (18–20 g) were anesthetized with a
mixture of xylazine and ketamine, , and placed on a circulating
water-heated bed. An abdominal mid section was made and the
mesentery adjacent to a segment of small intestine was exposed.
Then, the intestinal segment was positioned on a heated (37uC)
brass device that surrounded an optical window for observing the
lymphatic vessels [32]. The collecting lymphatic vessels selected for
the study were those having an active flow of lymph. After several
minutes of observation to ensure adequate lymph flow, the venom
or isolated toxins, dissolved in 50 mL of PBS, were applied directly
over the exposed intestinal segment. The doses used were 20, 50
and 100 mg for crude venom, 40 and 80 mg for myotoxin II, 40
and 100 mg for BaP1, and 10 mg for the thrombin-like enzyme. In
the case of venom from neonate specimens, a dose of 100 mg was
used. Toxin doses were selected on the basis of previous studies
and were able to induce myonecrosis, hemorrhage and defibrin-
ation, respectively [30,33,34]. Controls were performed by
applying 50 mL of PBS alone. A video was recorded for 15 min,
and then snap shots were taken at 30 second intervals. At the end
of the observation period, animals were sacrificed by an overdose
of anesthetic. In some experiments, after 15 min of incubation, a
portion of the mesentery, where lymphatic vessels were located,
was dissected out, cut in small pieces and added to Karnovsky’s
fixative (2.5% glutaraldehyde, 2% paraformaldehyde in 0.1 M
phosphate buffer, pH 7.2). Postfixation was performed with 1%
osmium tetroxide. Afterwards, samples were dehydrated in
ethanol and embedded in Spurr resin [35]. One micrometer
sections were cut and stained with toluidine blue for histological
observation. All animal experiments were approved by the
Institutional Committee for the Use and Care of Animals
(CICUA) of the University of Costa Rica.
Measurement of the area of the lymphatic vessels
The changes in the relative area of the lymphatics in time were
determined by quantification of the number of pixels correspond-
ing to the lumen of those vessels from snap shots taken every
30 seconds. Image analysis was performed using a routine
implemented in MATLAB (Mathworks) following morphological
criteria and intensity threshold filtering. In each assay the initial
area before the application of venom or toxins was considered as
100%, and the subsequent measurements were expressed in
percentage relative to this 100%. The effects on the lymph flow
were observed during 15 min after the application of the venom or
isolated toxins, and the time when lymph flow in the selected
lymphatic vessel stopped was recorded.
Experiments with inhibitors
The peptidomimetic metalloproteinase inhibitor Batimastat (4-
(N-hydroxyamino)-2R-isobutyl-3S-(thienylthiomethyl)-succinyl(-L-
phenylalanine-N-methylamide; molecular mass: 478) was provided
by British Biotech Pharmaceuticals, Ltd (Oxford, United King-
dom). All Batimastat suspensions were prepared by sonication in
PBS containing 0.01% Tween 80 (PBS-Tween). The concentra-
tions of Batimastat used were selected on the basis of our previous
studies [36,37]. A solution of 4 mg/mL of B. asper venom was
incubated with an equal volume of 200 mM batimastat for 60 min
Author Summary
Envenomations by snakes of the family Viperidae (pit
vipers) induce severe pathological alterations at the site of
venom injection, such as edema, necrosis, hemorrhage,
and blistering, which may lead to permanent tissue
damage and disability. Edema is a prominent and common
manifestation in these envenomations. The effect of
viperid snake venoms in lymphatic vessels has not been
previously investigated. This study analyzed the effect of
the venom of Bothrops asper, the most important
venomous snake in Central America, on the collecting
lymphatic vessels of the mouse mesentery. The venom
induced a rapid reduction in the lumen of these
lymphatics, associated with a halting in the flow of lymph.
These effects were reproduced by a myotoxic phospholi-
pase A2 homologue isolated from this venom, but not by a
hemorrhagic metalloproteinase nor by a coagulant serine
proteinase. B. asper venom, and the purified myotoxin,
were cytotoxic for smooth muscle cells in culture, thus
suggesting that the alterations observed in lymphatics are
due to the effect on smooth muscle cells of the lymphatic
vessel wall. These results demonstrate a direct effect of B.
asper venom on lymphatics, which is likely to contribute to
the prominent edema characteristic of these envenom-
ations.
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at 37uC. Controls included venom incubated without Batimastat,
and Batimastat incubated without venom. Inhibition of venom
metalloproteinases was demonstrated by assessing the elimination
of venom hemorrhagic activity in mice [37]. The polyanionic
polysaccharide fucoidan (molecular mass: 135 kDa; Sigma–
Aldrich, St. Louis, MO, USA) was used to inhibit myotoxic
PLA2s. Solutions of B. asper venom were incubated with fucoidan
at an inhibitor: venom weight ratio of 3:1 for 60 min at room
temperature. Controls included venom incubated without fucoi-
dan, and fucoidan incubated without venom. Inhibition of
myotoxic activity of PLA2s in these conditions was corroborated
in mice by determining the plasma creatine kinase (CK) activity in
plasma [38,39].
Inhibition of edema-forming activity by fucoidan
Edema-forming activity induced by venom and myotoxin II was
assessed by measuring the increment in the footpad thickness with
a low pressure spring caliper [40]. The ability of fucoidan to
inhibit venom and myotoxin-induced edema was evaluated by
incubating either venom or myotoxin with fucoidan, for 60 min at
room temperature, at an inhibitor: venom weight ratio of 3:1 or at
an inhibitor: toxin weight ratio of 10:1 (which corresponds
approximately to a molar ratio of 1:1). Controls included venom
or toxin incubated with PBS alone. Mice (18–20 g; n = 5) were
then injected subcutaneously, in the right foot pad, with 50 mL of
solutions containing either venom or toxin alone, or venom or
toxin incubated with fucoidan. The doses injected were 5 mg, in
the case of venom, and 6 mg, in the case of myotoxin. These doses
were selected on the basis of previous studies since they induce a
submaximal edema response [41,42]. The left foot pad was
injected with 50 mL of either PBS alone or fucoidan alone. At
various time intervals (15 and 30 min, and one, three and six hr),
the thickness of both footpads was determined. Edema was
expressed as the percentage increment in the thickness of the right
footpad as compared to the left one.
Cytotoxicity assays on smooth muscle cells
The human umbilical artery smooth muscle cell line
(HUASMC, Cell Applications, Inc., San Diego, CA) was used.
Smooth muscle cells were grown in 25 cm2 bottles using
Endothelial Cell Growth Medium (Cell Applications, San Diego,
CA, USA), in a humidified atmosphere with 7% CO2, at 37uC.
Subconfluent monolayers were treated, for 5 min at 37uC, with
trypsin (1500 U/mL), containing 5.3 mM EDTA. Resuspended
cells were seeded in 96-well microplates, at an approximate initial
density of 1–46103 cells per well, in the same culture medium.
Cytotoxicity was assessed by determining the release of the
cytosolic enzyme lactic dehydrogenase (LDH), as previously
described [43,44]. Briefly, smooth muscle cell cultures were
incubated with various concentrations of Myotoxin II, dissolved
in culture medium, at a volume of 100 mL/well. Aliquots of the
supernatant in culture wells were collected at 3 hours. LDH
activity was determined by using a commercial kit (Biocon LDH-
P, Analyticon Biotechnologies AG, Germany). Reference controls
for 0% and 100% cytolysis consisted of medium alone and
medium from cells incubated with 0.1% (v/v) of Triton X-100,
respectively. All assays were carried out in triplicates.
For inhibition studies, smooth muscle cells were incubated with
either crude B. asper venom or with B. asper venom previously
incubated, during 60 min at room temperature, with fucoidan. A
constant amount of fucoidan was incubated with various
concentrations of venom, and a ratio of fucoidan:venom of 3:1
(w:w) was achieved at the highest concentration of venom used.
After incubation, 100 mL of solutions, containing various doses of
venom, were added to cell culture wells, followed by 3 hr
incubation. LDH activity in the medium was determined as
described. All assays were performed in triplicates.
Analysis of permeability to propidium iodide in smooth
muscle cells
Smooth muscle cells were cultured as described. Culture wells
were then washed with PBS, followed by the addition of cell
culture medium containing 1% fetal calf serum (FCS), 1 mg/mL
propidium iodide (PI) and Myotoxin II (20 mg/well). Hoechst-
33258 (1 mg/mL; Sigma-Aldrich) was added to identify all cell
nuclei in the preparation. Cells were incubated at various time
intervals, and observed in a fluorescence microscope. This
methodology allowed the detection of plasma membrane damage
[45].
Statistical analyses
The significance of the differences between pairs of means was
determined by the Student’s t test, with a p value of 0.05
determining the limit of significance. When more than two groups
were compared, an analysis of variance was performed, followed
by a Tukey test.
Results
Intravital microscopy observations: Crude venom
reduces lymphatic vessel lumen and impairs lymphatic
flow
In order to study the effects of crude venom on lymphatic
vasculature, collecting lymphatics, located in the mesentery and
presenting the characteristic valves, were identified using intravital
microscopy (Fig 1). For analysis of the effect of venom, only
collecting lymphatics having a regular lymph flow were used.
Application of PBS alone did not induce any effect in the lumen of
these vessels, as evidenced by the maintenance of a constant area
in the lumen (Fig 2). When venom was applied onto the
mesentery, a dose-dependent effect was observed, characterized
by a significant contraction of the vessel wall, resulting in a
reduction of the lumen; such effect occurred within 2–5 min of
application of venom doses of 50 and 100 mg, but not with the
dose of 20 mg (Fig 2A, B and C). The effect remained at the end of
the 15 min observation period. When using doses of 50 and
100 mg, a complete halting of lymph flow occurred between 5 and
7 min after application of venom (Table 1). When using 50 mg of
venom, there was a restart of lymph flow at later time intervals,
whereas with the dose of 100 mg the flow was not recovered (not
shown). In addition, a prominent hemorrhage developed within
the first 5 min of application of the venom, evidenced by abundant
areas of extravasation. Many erythrocytes were observed flowing
through the lymphatics at early time periods, before the halting of
lymph flow. Histological observations corroborated the presence of
erythrocytes inside lymphatics (Fig 3). When a dose of 100 mg
venom of neonate B. asper specimens was tested, there was no effect
on the lumen of lymphatic vessels nor halting in lymph flow
(Fig 2D), but a prominent hemorrhage developed in the
mesentery.
Myotoxin II reproduces the effect of crude venom on
lymphatic vessels
To determine which component of the venom is responsible for
the activity on the lymphatic vessels, single isolated toxins were
tested. Application of BaP1, a hemorrhagic metalloproteinase, and
of a thrombin-like coagulant serine proteinase isolated from B.
Effect of Snake Venom on Lymphatics
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Figure 1. Light micrograph of a collecting lymphatic vessel in a mouse mesentery preparation, observed by intravital microscopy. A
characteristic valve is present (arrow). 2006.
doi:10.1371/journal.pntd.0000318.g001
Figure 2. Effect of B. asper venom on the caliber of mouse mesentery collecting lymphatic vessels. The mesentery was exposed as
described in Methods, and 50 mL of either PBS or various concentrations of B. asper venom, dissolved in 50 mL PBS, were applied onto the
preparation. A video was recorded before venom application and then during 15 min after venom addition. Snap shots were taken at 30 second
intervals. A section of the lymphatic was selected and the area of its lumen determined by an image analysis program for each snap shot. Changes in
the area were expressed as percentage, considering 100% the area of the lymphatic vessel lumen before the application of venom or PBS. Results are
presented as mean6S.E.M. of five different preparations. Open circles represent control samples treated with PBS alone and closed circles represent
samples treated with venom (A: 20 mg, B: 50 mg, C: 100 mg of venom from adult specimens, D: 100 mg of venom from neonate specimens). *p,0.05
when compared with control preparations treated with PBS alone.
doi:10.1371/journal.pntd.0000318.g002
Effect of Snake Venom on Lymphatics
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asper venom did not induce any effect in the lumen of lymphatics
(Fig 4 A,B), at doses inducing widespread hemorrhage, in the case
of BaP1, and defibrination, in the case of the thrombin-like
enzyme. In contrast, the PLA2 homologue myotoxin II reproduced
the effects induced by crude venom in lymphatics, since it induced
a dose-dependent reduction in the lumen of these vessels (Fig 4 C,
D) and a concomitant halting in the lymph flow (Table 1).
A myotoxin inhibitor abolishes the effect of the venom
on lymphatic vessels
To confirm that involvement of specific venom components in
the effect of crude venom on lymphatics, the ability of several
inhibitors to block the effect of B. asper venom was assessed.
Incubation of B. asper venom with the metalloproteinase inhibitor
Batimastat resulted in complete abrogation of hemorrhagic
activity, without preventing the lymphatic alterations induced by
the venom (Fig 5A). In contrast, incubation of venom with
fucoidan, a known inhibitor of myotoxic PLA2s, completely
abolished the effect of venom on the lymphatics (Fig 5B), without
affecting its hemorrhagic activity. Control preparations in which
Batimastat or fucoidan alone were applied to mesentery did not
show any observable effect (not shown).
A myotoxin inhibitor significantly reduces edema-
forming activity of venom
In order to assess whether inhibition of myotoxin has an effect
on edema-forming activity, venom or myotoxin II were incubated
with fucoidan and edema was tested in the mouse footpad model.
Fucoidan completely abolished edema-forming activity of myo-
toxin II (Fig 6A). Moreover, fucoidan markedly reduced the
edema-forming activity of B. asper venom (Fig 6B), thus evidencing
that myotoxins play a significant role in the pathogenesis of edema
induced by this venom.
Myotoxin II induces cytotoxicity in smooth muscle cells
In order to gain insights into the mechanism through which B.
asper venom affects lymphatics, cultured smooth muscle cells were
treated with myotoxin II. Myotoxin induced a rapid and dose-
dependent cytotoxicity, evidenced by the release of the cytosolic
enzyme LDH (Fig 7). The toxin also induced a rapid increment in
the permeability of plasma membrane to PI (Fig 8) which
corroborated the disruption in the integrity of plasma membrane.
Moreover, incubation of B. asper venom with fucoidan, prior to its
addition to smooth muscle cell culture completely abrogated
cytotoxicity in these cells (Fig 9), thus confirming the relevance of
basic myotoxins in this effect.
Discussion
Lymphatic vessels play a key role in the fluid and pressure
balances in tissues, by regulating fluid homeostasis. This function is
Table 1. Time required for the complete halting of lymph flow
in collecting lymphatics after application of B. asper venom or
purified toxins.
Treatment
Time required for halting
of lymph flow (min)
PBS -*
20 mg of B. asper venom -
50 mg of B. asper venom 7.3060.99
100 mg of B. asper venom 5.5060.40**
100 mg B. asper venom treated with
Batimastat
6.0560.87
100 mg B. asper venom treated with
fucoidan
-
100 mg of BaP1 -
10 mg of thrombin-like enzyme -
40 mg of MT-II 6.7060.82
80 mg of MT-II 5.3060.60**
*(-) indicates that lymph flow was not halted during the 15 min of observation.
**p,0.05 when compared with results obtained after application of 50 mg of B.
asper venom. Values represent mean6S.D. (n = 5).
doi:10.1371/journal.pntd.0000318.t001
Figure 3. Histological alterations in lymphatic vessels of mouse
mesentery preparations treated with B. asper venom. PBS (A) or
100 mg B. asper venom (B) were applied onto mouse mesentery, as
described in Methods. After 15 min, preparations were dissected out
and processed for histological observation. Notice the presence in B of
abundant erythrocytes within the lymphatic vessel lumen, as a
consequence of the hemorrhagic effect of the venom. Toluidine blue
staining. 1,0006.
doi:10.1371/journal.pntd.0000318.g003
Effect of Snake Venom on Lymphatics
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performed by two main types of vessels, i.e. the initial lymphatics
and the collecting, or contractile, lymphatics [46,47]. The initial
lymphatics are blind-ending vessels constituted by an endothelial
cell lining, characterized by a discontinuous basement membrane,
and are devoid of pericytes and smooth muscle cells [21,46,48].
Collecting lymphatics are characterized by the presence of a
smooth muscle cell layer which exhibits periodic contractions
regulated by transmural pressure, luminal lymph flow, neural
input and humoral factors [46,48,49]. Such contractile activity
depends on the regulation of Ca2+ fluxes in muscle cells [50]. A
system of valves is present in collecting lymphatics, allowing the
directional fluid transport along these vessels through functional
units known as lymphangions [46,47,49]. Our results demonstrate
a conspicuous effect of B. asper venom on the collecting lymphatics
of the mouse mesentery.
An intravital microscopy methodology was used, coupled to an
image analysis system, to follow the morphological alterations in
lymphatics, to quantify the extent of reduction in their lumen, and
to assess the halting of lymph flow. It allowed the determination of
the area of a segment of a lymphatic vessel, which is directly
proportional to the lumen of the vessel. The most notorious
observation upon the local application of B. asper venom was a
dose-dependent reduction in the lumen of the vessel, with a
concomitant halting in the flow of lymph. Such effects had a rapid
onset and were prolonged for the 15 min of observation.
Interestingly, in most cases, the reduction in lymphatic vessel
diameter preceded the halting of lymph flow. Experiments
performed with toxins isolated from this venom showed that these
effects were reproduced by a myotoxic PLA2 homologue, but not
by a hemorrhagic metalloproteinase or by a coagulant serine
proteinase. The lack of involvement of metalloproteinases in the
pathogenesis of this effect was further corroborated by the inability
of Batimastat, a potent metalloproteinase inhibitor [37], to
abrogate the effect. Metalloproteinases are responsible for the
main alterations induced by viperid venoms in the microvascula-
ture, resulting in capillary disruption and hemorrhage [16,51].
Furthermore, our observations showed that the venom of
neonate specimens of B. asper does not induce lymphatic vessel
damage. There are drastic differences in the composition of
venoms from neonate and adult specimens of B. asper [52,53].
Venom of neonates has a high concentration of metalloproteinases
and, consequently, a higher hemorrhagic activity than venom of
adults. In contrast, venom of neonates is devoid of myotoxic PLA2s
[52,54], whereas myotoxins are abundant in the venom of adults
[52,54,55]. The lack of effect on lymphatics of strongly
hemorrhagic and weakly myotoxic neonate B. asper venom further
supports a key role of basic myotoxic PLA2s and PLA2
homologues, and the lack of involvement of hemorrhagic
metalloproteinases, in the pathogenesis of lymphatic vessel
damage.
Figure 4. Effect of isolated toxins on the caliber of mouse mesentery collecting lymphatic vessels. The mesentery was exposed as
described in Methods, and 50 mL of either PBS or different toxins isolated from B. asper venom, dissolved in 50 mL PBS, were applied onto the
preparation. Observations were performed as described in the legend of Fig 2. Changes in the area were expressed as percentage, considering 100%
the area of the lymphatic vessel lumen before the application of toxins or PBS. Results are presented as mean6S.E.M. of five different preparations.
Open circles represent control samples treated with PBS alone and closed circles represent samples treated with toxins: (A) 100 mg of hemorrhagic
metalloproteinase BaP1; (B) 10 mg of coagulant thrombin-like serine proteinase; (C) 40 mg of the phospholipase A2 homologue myotoxin II; (D) 80 mg
of myotoxin II. *p,0.05 when compared with control preparations treated with PBS alone.
doi:10.1371/journal.pntd.0000318.g004
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The lack of effect of metalloproteinase on lymphatics may be
related to the fluid pressure within these vessels. It has been
observed that B. asper SVMPs do not directly affect the integrity of
endothelial cells in culture [34,56,57]. Therefore, the drastic
ultrastructural alterations induced in capillary endothelial cells in
vivo are likely to depend on the biophysical hemodynamic forces
operating in vivo, which promote distension and rupture of
endothelium after the initial weakening of capillary wall structure
provoked by the SVMP-induced cleavage of basement membrane
components [51,58]. Therefore, in a low-pressure system, such as
that of lymphatic vessels, the degradation of basement membrane
components would not result in the distension and disruption of
vessel integrity. In addition, the presence of a muscle cell layer
surrounding endothelium in the collecting lymphatics provides a
mechanical protection to the effect of basement membrane
degradation. The role of a thrombin-like coagulant enzyme was
assessed in order to test whether clotting of fibrinogen in the lymph
would affect lymph flow. Results clearly evidenced that coagulant
and procoagulant components, which are common in viperid
snake venoms [59] and have been described in B. asper venom
[30,60], are not responsible for the effect of venom on lymphatics.
The pathological effects induced by B. asper venom on
lymphatics were reproduced by myotoxin II, a myotoxic PLA2
homologue. Furthermore, the key role played by this type of
component was corroborated by the complete elimination of the
effect when venom was preincubated with fucoidan, an inhibitor of
myotoxic PLA2s [38,39]. B. asper venom, and many other viperid
venoms, contain a group of highly cationic PLA2s and PLA2
homologues which are responsible for skeletal muscle damage, i.e.
myonecrosis [15]. Many of these myotoxins, such as the one used
in this study, are catalytically-inactive variants, known as Lys49
PLA2s, able to disrupt membranes and to induce myonecrosis
[61]. Our observations provide evidence, for the first time, that
myotoxic PLA2s are also capable of damaging smooth muscle cells
with a dose-dependency range similar to that previously described
for skeletal muscle myotubes in culture [44]. It is suggested that
myotoxin II affects smooth muscle cells by disrupting the integrity
of the plasma membrane, thus promoting a Ca2+ influx and, at
Figure 5. Effect of metalloproteinase inhibitor Batimastat and
myotoxin inhibitor fucoidan on the activity of B. asper venom
on mouse mesentery collecting lymphatics. Before application,
venom solutions were incubated with either Batimastat or fucoidan, as
described in Methods. The mesentery was exposed and 50 mL of either
PBS or the mixtures of 100 mg venom and inhibitors, dissolved in 50 mL
PBS, were applied onto the preparation. Observations were performed
as described in the legend of Fig 2. Changes in the area were expressed
as percentage, considering 100% the area of the lymphatic vessel
lumen before the application of venom or PBS. Results are presented as
mean6S.E.M. of five different preparations. Open circles represent
control samples treated with PBS alone and closed circles represent
samples treated with venom incubated with Batimastat (A) or fucoidan
(B). *p,0.05 when compared with control preparations treated with
PBS alone.
doi:10.1371/journal.pntd.0000318.g005
Figure 6. Inhibition of edema-forming activity of myotoxin II
and B. asper venom by fucoidan. Myotoxin II (A) or venom (B) were
incubated with fucoidan, and edema was assessed at various time
intervals after subcutaneous injection in the footpads of mice, as
described in Methods. Edema was expressed as the percentage of
increment in the thickness of the footpad as compared with the
contralateral footpad that was injected with either PBS or fucoidan
alone. Closed triangles and circles correspond to edema induced by
myotoxin or venom alone, whereas open triangles and circles
correspond to edema induced by myotoxin or venom incubated with
fucoidan. Results are presented as mean6S.E.M. (n = 5). Edema was
significantly reduced (p,0.05) by fucoidan at all time intervals tested.
doi:10.1371/journal.pntd.0000318.g006
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cytotoxic concentrations, the release of the cytosolic enzyme LDH
and the influx of PI. Such membrane perturbation, with the
concomitant increment in cytosolic Ca2+ concentration, would
promote muscle cell contraction [49,50] and the consequent
reduction in lymphatic vessel lumen. The sustained contraction of
lymphatic smooth muscle precludes the process of cyclic
contractility, characteristic of normal lymphatic vessels, which
promotes lymph pumping [49]; as a consequence, the flow of
lymph is halted. Furthermore, a sustained increment in cytosolic
Ca2+ would trigger a series of degenerative events that provoke
irreversible cell damage, i.e. necrosis [15]. In this scenario,
lymphatic smooth muscle cells would be irreversibly damaged and,
therefore, the vessel would be functionally impaired since lymph
flow requires a coordinated tonic and phasic contraction of smooth
muscle in collecting lymphatics [49]. Hence, although our
intravital observations allowed the observation of acute changes
only, the observed cytotoxicity on smooth muscle cells suggests
that venom-induced lymphatic damage is likely to be long lasting,
with evident pathophysiological implications. Besides the cytotox-
ic, i.e. pathological effect of myotoxins in lymphatic vessel smooth
muscle cells, the observed contraction may be also due to the
PLA2-induced release of inflammatory mediators [62], some of
which may promote smooth muscle contraction.
Our results shed light into a hitherto unknown aspect of snake
venom-induced local pathology which may have a relevant
pathophysiological role. Viperid snakebite envenomations are
characterized, among other features, by a prominent edema of
rapid onset which is very difficult to manage therapeutically [63].
Pharmacological studies have identified a number of inflammatory
mediators involved in this edema-forming activity of Bothrops sp
venoms [41,62,64]. The described effect of B. asper venom on
collecting lymphatics highlights another possible mechanism for
the pathogenesis of edema, since the alterations described are
likely to affect the lymph flow in envenomated tissues. Our
observation that the myotoxin inhibitor fucoidan drastically
reduces venom-induced edema supports the hypothesis that basic
myotoxic PLA2s and PLA2 homologues play a key role in the
pathogenesis of edema by this venom. Thus, the edematogenic
action of myotoxic PLA2s may be due to a combination of their
effect on lymphatic vessels and their ability to release inflammatory
mediators in the tissue [42,62].
Figure 7. Cytotoxic activity of B. asper myotoxin II on smooth
muscle cells in culture. Cells were seeded in 96-well microplates, at
an approximate initial density of 1–46103 cells per well, and were
incubated with various concentrations of myotoxin II, dissolved in
culture medium, at a volume of 100 mL/well. Aliquots of the
supernatant in culture wells were collected at 3 hr and LDH activity
was determined, and expressed as percentage LDH release. Reference
controls for 0% and 100% release consisted of medium alone and
medium from cells incubated with 0.1% (v/v) of Triton X-100,
respectively. Results are presented as mean6S.E.M. (n = 3).
doi:10.1371/journal.pntd.0000318.g007
Figure 8. Plasma membrane disruption of smooth muscle cells
by the action of myotoxin II. Cells, seeded as described in the
legend of Fig 7, were incubated with myotoxin II (20 mg per well in cell
culture microplates) and 1 mg/mL of propidium iodide (PI), both
dissolved in cell culture medium containing 1% FCS. (A) Cells incubated
with medium alone, without toxin, showing no penetration of PI. (B)
Cells incubated with myotoxin, evidencing penetration of PI after 5 min
of incubation. (C) The same microscopic field of (B), stained with
Hoechst-33258 to visualize the nuclei of all cells. 4006.
doi:10.1371/journal.pntd.0000318.g008
Effect of Snake Venom on Lymphatics
www.plosntds.org 8 October 2008 | Volume 2 | Issue 10 | e318
Our findings may also explain previous observations showing
that, at low venom doses, there is a transient edema that peaks
early on after injection and then declines [40], whereas when
higher venom doses are administered, swelling has an extended
time-course [40,41]. It is suggested that such prolonged edema is
the consequence of the pathological alterations described in
lymphatic vessels, with the consequent impairment in lymph
formation and interstitial fluid balance. Since local edema may
complicate local pathology by promoting increments in interstitial
pressure in muscle compartments, leading potentially to compart-
mental syndrome-associated ischemia and necrosis, lymphatic
vessel damage is a significant component of snake venom-induced
pathology that deserves consideration at experimental and clinical
settings. Our results also suggest that inhibition of the cytotoxic
action of venom myotoxins in smooth muscle cells may be of
therapeutic benefit in snakebite envenomation.
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